Roles of MicroRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Aug 28

PMID 32850313

Citations 44

Authors

Ali A Alshamrani

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the top gynecological malignancies that cause deaths among females in the United States. At the molecular level, significant progress has been made in our understanding of ovarian cancer development and progression. MicroRNAs (miRNAs) are short, single-stranded, highly conserved non-coding RNA molecules (19-25 nucleotides) that negatively regulate target genes post-transcriptionally. Over the last two decades, mounting evidence has demonstrated the aberrant expression of miRNAs in different human malignancies, including ovarian carcinomas. Deregulated miRNAs can have profound impacts on various cancer hallmarks by repressing tumor suppressor genes. This review will discuss up-to-date knowledge of how the aberrant expression of miRNAs and their targeted genes drives ovarian cancer initiation, proliferation, survival, and resistance to chemotherapies. Understanding the mechanisms by which these miRNAs affect these hallmarks should allow the development of novel therapeutic strategies to treat these lethal malignancies.

Citing Articles

Extracellular Regucalcin: A Potent Suppressor in the Cancer Cell Microenvironment.

Yamaguchi M Cancers (Basel). 2025; 17(2).

PMID: 39858022 PMC: 11763602. DOI: 10.3390/cancers17020240.

Exploring the Shared Pathogenesis Mechanisms of Endometriosis and Cancer: Stemness and Targeted Treatments of Its Molecular Pathways-A Narrative Review.

Mitranovici M, Costachescu D, Voidazan S, Munteanu M, Buicu C, Oala I Int J Mol Sci. 2024; 25(23).

PMID: 39684461 PMC: 11640855. DOI: 10.3390/ijms252312749.

miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.

Wang X, Woo H, Wei M, Gibson S, Miranda M, Rush D Sci Rep. 2024; 14(1):29937.

PMID: 39622842 PMC: 11611913. DOI: 10.1038/s41598-024-80173-z.

Comprehensive analysis of electrochemical biosensors for early ovarian cancer detection.

El-Gammal M, Sayed F, Allam N RSC Adv. 2024; 14(50):37580-37597.

PMID: 39588243 PMC: 11587864. DOI: 10.1039/d4ra05972g.

miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles.

Alshamrani A, Bin Salman S, Alsaleh N, Assiri M, Almutairi M, Almudimeegh S Saudi Pharm J. 2024; 32(11):102169.

PMID: 39318640 PMC: 11421238. DOI: 10.1016/j.jsps.2024.102169.

References

Shi J, Liu Y, Xu X, Zhang W, Yu T, Jia J . Deubiquitinase USP47/UBP64E Regulates β-Catenin Ubiquitination and Degradation and Plays a Positive Role in Wnt Signaling. Mol Cell Biol. 2015; 35(19):3301-11. PMC: 4561727. DOI: 10.1128/MCB.00373-15. View

Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S . Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol. 2014; 11(5):495-502. PMC: 4197204. DOI: 10.1038/cmi.2014.30. View

Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F . DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Overexpression in Cancer Cells. Theranostics. 2017; 7(17):4118-4134. PMC: 5695001. DOI: 10.7150/thno.20112. View

Calura E, Fruscio R, Paracchini L, Bignotti E, Ravaggi A, Martini P . MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res. 2013; 19(15):4114-23. DOI: 10.1158/1078-0432.CCR-13-0360. View

Prasad S, Yadav S, Das M, Govardhan H, Pandey L, Singh S . Down Regulation of FOXO1 Promotes Cell Proliferation in Cervical Cancer. J Cancer. 2014; 5(8):655-62. PMC: 4142327. DOI: 10.7150/jca.6554. View

Vera-Puente O, Rodriguez-Antolin C, Salgado-Figueroa A, Michalska P, Pernia O, Reid B . MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species. Transl Res. 2018; 200:1-17. PMC: 7787305. DOI: 10.1016/j.trsl.2018.06.005. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Liu X, Yang W, Zheng P . Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget. 2014; 5(21):10870-85. PMC: 4279416. DOI: 10.18632/oncotarget.2539. View

10.

Langhe R, Norris L, Saadeh F, Blackshields G, Varley R, Harrison A . A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 2014; 356(2 Pt B):628-36. DOI: 10.1016/j.canlet.2014.10.010. View

11.

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

12.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

13.

Guo P, Xiong X, Zhang S, Peng D . miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep. 2016; 36(6):3552-3558. DOI: 10.3892/or.2016.5140. View

14.

Tysnes B, Bjerkvig R . Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta. 2007; 1775(2):283-97. DOI: 10.1016/j.bbcan.2007.01.001. View

15.

Fenton T, Gout I . Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol. 2010; 43(1):47-59. DOI: 10.1016/j.biocel.2010.09.018. View

16.

van Jaarsveld M, Helleman J, Boersma A, van Kuijk P, van Ijcken W, Despierre E . miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2012; 32(36):4284-93. DOI: 10.1038/onc.2012.433. View

17.

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

18.

Yang T, Yang X, Wang X, Wang Y, Zhou B, Song Z . MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int. 2013; 13(1):68. PMC: 3716801. DOI: 10.1186/1475-2867-13-68. View

19.

Visser S, Yang X . LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle. 2010; 9(19):3892-903. DOI: 10.4161/cc.9.19.13386. View

20.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J . Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 10(8):788-95. DOI: 10.4161/cbt.10.8.12913. View